telmisartan has been researched along with Cardiovascular Stroke in 40 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (25.00) | 29.6817 |
| 2010's | 26 (65.00) | 24.3611 |
| 2020's | 4 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kawada, T; Li, M; Saku, K; Sawada, S; Suehara, S; Sugimachi, M; Uemura, K; Zheng, C | 1 |
| Jeong, HE; Kim, JS; Ko, H; Lim, MJ; Shin, JY; Yoo, YG | 1 |
| Finger, S; Garlapati, V; Karbach, SH; Knopp, T; Knorr, M; Kossmann, S; Lagrange, J; Molitor, M; Münzel, T; Nguyen, TS; Rudi, WS; Ruf, W; Schüler, R; Wenzel, P; Wild, J | 1 |
| Cai, Y; Chen, M; Li, H; Li, Z; Ma, S; Ou, C; Wen, Z; Xu, G; Yang, Z; Zhan, J; Zhang, J | 1 |
| Chang, HY; Li, X; Tian, Y | 1 |
| Böhm, M; Lonn, E; Mahfoud, F; Mancia, G; Mann, JFE; Redon, J; Schmieder, R; Schumacher, H; Sliwa, K; Teo, KK; Weber, M; Williams, B; Yusuf, S | 1 |
| Böhm, M; Lonn, EM; Mahfoud, F; Mancia, G; Mann, JFE; Marx, N; Redon, J; Schmieder, RE; Schumacher, H; Sliwa, K; Teo, KK; Weber, MA; Williams, B; Yusuf, S | 1 |
| D'Amico, M; Ferraro, B; Gulotta, E; Messina, A; Nicoletti, GF; Panarese, I; Pieretti, G; Trotta, MC | 1 |
| Antoniou, T; Camacho, X; Gomes, T; Juurlink, DN; Mamdani, MM; Yao, Z | 1 |
| Böhm, M; Laufs, U; Schmieder, R; Schumacher, H; Sleight, P; Teo, K; Unger, T; Yusuf, S | 1 |
| Clase, C; Dagenais, GR; de Zeeuw, D; Gao, P; Heerspink, HJ; Lonn, E; Mann, JF; Sleight, P; Teo, KT; Yusuf, S | 1 |
| Haririan, A; Karadsheh, FF; Reddivari, V; Salzberg, DJ; Weir, MR | 1 |
| Böhm, M; Foulquier, S; Schmieder, R; Schumacher, H; Sleight, P; Teo, K; Unger, T; Yusuf, S | 1 |
| Bath, PM; Cotton, D; Estol, CJ; Gorelick, PB; Martin, RH | 1 |
| D'Amico, M; De Angelis, A; Di Filippo, C; Ferraraccio, F; Ferraro, B; Maisto, R; Rossi, C; Rotondo, A | 1 |
| Lackland, DT | 1 |
| Angeli, F; Gao, P; Mancia, G; Pogue, J; Reboldi, G; Sleight, P; Teo, K; Trimarco, B; Verdecchia, P; Yusuf, S | 1 |
| Bai, J; Song, Z; Sun, X; Zhang, J; Zhang, L; Zhang, M; Zheng, H | 1 |
| Dash, R; Harnish, P; Kim, PJ; McConnell, MV; Nishimura, D; Toma, I; Yang, PC | 1 |
| Albers, GW; Bath, P; Bornstein, N; Chan, BP; Chen, ST; Cotton, D; Cunha, L; Dahlöf, B; De Keyser, J; Diener, HC; Donnan, GA; Estol, C; Gorelick, P; Gu, V; Hermansson, K; Hilbrich, L; Kaste, M; Lawton, WA; Lu, C; Machnig, T; Martin, RH; Ounpuu, S; Pais, P; Palesch, Y; Roberts, R; Sacco, RL; Skvortsova, V; Teal, P; Toni, D; Vandermaelen, C; Voigt, T; Weber, M; Yoon, BW; Yusuf, S | 2 |
| Hall, A; Strauss, MH | 1 |
| Arora, S; Arya, DS; Goyal, S; Joshi, S; Kumari, S; Mittal, R; Nag, TC; Ray, R | 1 |
| Arora, S; Arya, DS; Bhatt, TK; Das, P; Goyal, S; Kumari, S; Sharma, A | 1 |
| Abe, N; Hanada, H; Hanada, K; Higuma, T; Kushibiki, M; Oikawa, K; Okumura, K; Osanai, T; Tomita, H; Yokota, T; Yokoyama, J | 1 |
| Clase, CM; Gao, P; Grosshennig, A; Mann, JF; McQueen, M; Teo, KK; Tobe, SW; Wang, X; Yusuf, S | 1 |
| Haraguchi, G; Isobe, M; Kosuge, H; Maejima, Y; Okada, H; Onai, Y; Suzuki, J | 1 |
| Ruilope, LM | 1 |
| Avezum, A; Dans, A; Ferreira, R; Gafni, A; Gao, P; Lamy, A; Teo, K; Tong, W; Wang, X; Young, J; Yusuf, S | 1 |
| Bath, PM; Cotton, D; Diener, HC; Donnan, GA; Martin, RH; Ovbiagele, B; Vinisko, R; Yusuf, S | 1 |
| Hirata, Y; Hishikari, K; Isobe, M; Masumura, M; Nagai, R; Nagashima, A; Ogawa, M; Shimizu, T; Suzuki, J; Takayama, K; Watanabe, R | 1 |
| Böhm, M; Kappert, K; Schmieder, R; Schumacher, H; Sleight, P; Teo, K; Unger, T; Yusuf, S | 1 |
| Guirguis-Blake, J | 1 |
| Han, J; Kim, HK; Kim, N; Ko, KS; Ko, TH; Lee, SR; Lee, SY; Lim, SE; Long, le T; Nilius, B; Noh, JH; Rhee, BD; Won, du N; Youm, JB | 1 |
| Drexler, H; Fuchs, M; Grote, K; Hilfiker, A; Hilfiker-Kleiner, D; Kaminska, A; Kaminski, K; Kiian, I; Klein, G; Podewski, E; Wollert, KC | 1 |
| Abe, N; Fujiwara, T; Hanada, H; Higuma, T; Kimura, M; Oikawa, K; Okumura, K; Osanai, T; Sasaki, S; Tomita, H; Yokota, T; Yokoyama, H; Yokoyama, J | 1 |
2 review(s) available for telmisartan and Cardiovascular Stroke
| Article | Year |
|---|---|
Telmisartan for the management of patients at high cardiovascular risk.
Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cost of Illness; Heart Failure; Humans; Myocardial Infarction; PubMed; Ramipril; Telmisartan; Time Factors | 2011 |
Adding ACE inhibitors or ARBs to standard therapy for stable ischemic heart disease.
Topics: Adrenergic beta-Antagonists; Angioedema; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Cough; Dizziness; Drug Therapy, Combination; Headache; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Patient Readmission; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stroke; Telmisartan | 2012 |
13 trial(s) available for telmisartan and Cardiovascular Stroke
| Article | Year |
|---|---|
Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120-140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Ramipril; Risk Assessment; Single-Blind Method; Stroke; Telmisartan; Treatment Outcome | 2018 |
Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Blood Pressure Determination; Cardiovascular Diseases; Case-Control Studies; Diabetes Mellitus; Diastole; Drug Therapy, Combination; Heart Failure; Hospitalization; Humans; Hypertension; Myocardial Infarction; Peripheral Arterial Disease; Ramipril; Retrospective Studies; Risk Factors; Stroke; Systole; Telmisartan | 2019 |
Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Drug Therapy, Combination; Female; Humans; Male; Medication Adherence; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Ramipril; Risk; Telmisartan | 2013 |
The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Creatinine; Drug Therapy, Combination; Female; Heart Failure; Hospitalization; Humans; Hyperkalemia; Hypertension; Hypokalemia; Kidney; Kidney Diseases; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Nonlinear Dynamics; Odds Ratio; Potassium; Proportional Hazards Models; Ramipril; Renal Dialysis; Renin-Angiotensin System; Risk Assessment; Risk Factors; Stroke; Telmisartan; Time Factors; Treatment Outcome | 2014 |
Specific management of anemia and hypertension in renal transplant recipients: influence of renin-angiotensin system blockade.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Benzimidazoles; Benzoates; Darbepoetin alfa; Double-Blind Method; Erythropoietin; Female; Hemoglobins; Humans; Hypertension; Kidney Transplantation; Male; Middle Aged; Myocardial Infarction; Renin-Angiotensin System; Stroke; Telmisartan; Treatment Outcome; Young Adult | 2014 |
Impact of telmisartan on cardiovascular outcome in hypertensive patients at high risk: a Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease subanalysis.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Benzoates; Cardiovascular Diseases; Cardiovascular System; Coronary Artery Disease; Female; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Middle Aged; Myocardial Infarction; Peripheral Vascular Diseases; Stroke; Telmisartan; Treatment Outcome | 2014 |
Differences in ischemic and hemorrhagic recurrence rates among race-ethnic groups in the PRoFESS secondary stroke prevention trial.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Drug Therapy, Combination; Ethnicity; Female; Humans; Intracranial Hemorrhages; Ischemia; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Secondary Prevention; Stroke; Telmisartan | 2014 |
Systolic and diastolic blood pressure changes in relation with myocardial infarction and stroke in patients with coronary artery disease.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Pressure; Coronary Artery Disease; Diastole; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Myocardial Infarction; Ramipril; Stroke; Systole; Telmisartan; Time Factors; Treatment Outcome | 2015 |
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; Clopidogrel; Delayed-Action Preparations; Dipyridamole; Double-Blind Method; Drug Therapy, Combination; Factor Analysis, Statistical; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Risk; Secondary Prevention; Stroke; Telmisartan; Ticlopidine; Vascular Diseases | 2008 |
Telmisartan to prevent recurrent stroke and cardiovascular events.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Pressure; Cardiovascular Diseases; Creatinine; Diabetes Mellitus; Female; Follow-Up Studies; Heart Failure; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Potassium; Secondary Prevention; Stroke; Telmisartan; Treatment Failure | 2008 |
Effects of telmisartan on markers of ventricular remodeling in patients with acute myocardial infarction: comparison with enalapril.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Biomarkers; C-Reactive Protein; Chi-Square Distribution; Enalapril; Female; Humans; Inflammation Mediators; Japan; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Middle Aged; Myocardial Infarction; Prospective Studies; Radiography; Serum Amyloid P-Component; Stroke Volume; Telmisartan; Time Factors; Treatment Outcome; Ventricular Function, Left; Ventricular Remodeling | 2010 |
Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.
Topics: Aged; Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Creatinine; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Heart Failure; Heart Rate; Humans; Kidney Failure, Chronic; Male; Middle Aged; Myocardial Infarction; Ramipril; Stroke; Telmisartan; Treatment Outcome | 2011 |
Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in Combinatio
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Female; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Ramipril; Research Design; Risk Assessment; Risk Factors; Sex Distribution; Sex Factors; Stroke; Telmisartan | 2012 |
25 other study(ies) available for telmisartan and Cardiovascular Stroke
| Article | Year |
|---|---|
Angiotensin II inhibition increases diuresis during acute sympathetic activation in intact and denervated kidneys in rats with chronic myocardial infarction.
Topics: Angiotensin II; Animals; Blood Pressure; Diuresis; Kidney; Myocardial Infarction; Rats; Rats, Inbred WKY; Sympathetic Nervous System; Telmisartan | 2022 |
Risk of myocardial infarction, heart failure, and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan in patients.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Cerebrovascular Disorders; Heart Failure; Humans; Irbesartan; Losartan; Myocardial Infarction; Retrospective Studies; Telmisartan; Tetrazoles; Valsartan | 2023 |
Nox2+ myeloid cells drive vascular inflammation and endothelial dysfunction in heart failure after myocardial infarction via angiotensin II receptor type 1.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Genetically Modified; Disease Models, Animal; Endothelial Cells; Heart Failure; Leukocyte Rolling; Macrophages; Male; Mice, Inbred C57BL; Monocytes; Muramidase; Myeloid Cells; Myocardial Infarction; NADPH Oxidase 2; Oxidative Stress; Receptor, Angiotensin, Type 1; Signal Transduction; Telmisartan; Vasculitis | 2021 |
Dual-ligand supramolecular nanofibers inspired by the renin-angiotensin system for the targeting and synergistic therapy of myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cells, Cultured; Drug Delivery Systems; Heart Failure; Inflammation Mediators; Ligands; Male; Mice; Mice, Inbred C57BL; Molecular Targeted Therapy; Multifunctional Nanoparticles; Myocardial Infarction; Myocytes, Cardiac; Nanofibers; Precision Medicine; Rats; Reactive Oxygen Species; Renin-Angiotensin System; Telmisartan | 2021 |
Telmisartan reduces arrhythmias through increasing cardiac connexin43 by inhibiting IL-17 after myocardial infarction in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Arrhythmias, Cardiac; Benzimidazoles; Benzoates; Connexin 43; Electric Stimulation; Heart; Immunohistochemistry; Interleukin-17; Male; Myocardial Infarction; Myocardium; Rats; Rats, Sprague-Dawley; Telmisartan | 2017 |
Telmisartan cardioprotects from the ischaemic/hypoxic damage through a miR-1-dependent pathway.
Topics: Animals; Cell Hypoxia; Cell Line; Cell Survival; Connexin 43; KCNQ1 Potassium Channel; Male; MicroRNAs; Myocardial Infarction; Myocardial Reperfusion Injury; Myocytes, Cardiac; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Sprague-Dawley; Telmisartan | 2019 |
Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Benzimidazoles; Benzoates; Biphenyl Compounds; Diabetic Angiopathies; Dose-Response Relationship, Drug; Female; Heart Failure; Humans; Irbesartan; Losartan; Male; Myocardial Infarction; Proportional Hazards Models; Retrospective Studies; Stroke; Telmisartan; Tetrazoles; Treatment Outcome | 2013 |
Involvement of proteasome and macrophages M2 in the protection afforded by telmisartan against the acute myocardial infarction in Zucker diabetic fatty rats with metabolic syndrome.
Topics: Animals; Benzimidazoles; Benzoates; Macrophages; Metabolic Syndrome; Myocardial Infarction; Proteasome Endopeptidase Complex; Rats; Rats, Zucker; Telmisartan | 2014 |
Systolic blood pressure target levels: evidence for benefits in stroke.
Topics: Benzimidazoles; Benzoates; Blood Pressure; Coronary Artery Disease; Female; Humans; Male; Myocardial Infarction; Ramipril; Stroke; Telmisartan | 2015 |
[Effects of telmisartan on inflammation and fibrosis after acute myocardial infarction in rats].
Topics: Animals; Anterior Wall Myocardial Infarction; Benzimidazoles; Benzoates; C-Reactive Protein; Chemokine CCL2; Drugs, Chinese Herbal; Fibrosis; Inflammation; Interleukin-1beta; Interleukin-6; Matrix Metalloproteinase 9; Myocardial Infarction; Myocardium; NF-kappa B; Rats; Telmisartan; Tumor Necrosis Factor-alpha | 2014 |
Telmisartan in the diabetic murine model of acute myocardial infarction: dual contrast manganese-enhanced and delayed enhancement MRI evaluation of the peri-infarct region.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Benzimidazoles; Benzoates; Contrast Media; Diabetes Mellitus, Type 2; Disease Models, Animal; Endothelial Progenitor Cells; Fibrosis; Flow Cytometry; Gadolinium DTPA; Magnetic Resonance Imaging; Manganese; Mice, Inbred C57BL; Mice, Transgenic; Microscopy, Electron, Transmission; Myocardial Infarction; Myocardium; Myocytes, Cardiac; Predictive Value of Tests; Recovery of Function; Stroke Volume; Telmisartan; Time Factors; Tissue Survival; Ventricular Function, Left | 2016 |
Telmisartan in high-risk patients intolerant of ACE inhibitors.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Statistics as Topic; Telmisartan | 2009 |
Myocardial salvaging effect of telmisartan in experimental model of myocardial infarction.
Topics: Animals; Benzimidazoles; Benzoates; Biomarkers; Body Weight; Cardiotonic Agents; Catalase; Disease Models, Animal; Heart; Isoproterenol; L-Lactate Dehydrogenase; Lipid Peroxidation; Male; Myocardial Infarction; Myocardium; Rats; Rats, Wistar; Superoxide Dismutase; Telmisartan | 2009 |
Modulation of PPAR-gamma by telmisartan protects the heart against myocardial infarction in experimental diabetes.
Topics: Animals; Benzimidazoles; Benzoates; Cardiotonic Agents; Diabetes Mellitus, Experimental; Disease Models, Animal; Heart; Male; Myocardial Infarction; Myocardium; PPAR gamma; Rats; Rats, Wistar; Telmisartan | 2010 |
Telmisartan, a unique ARB, improves left ventricular remodeling of infarcted heart by activating PPAR gamma.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Connective Tissue Growth Factor; Echocardiography; Enzyme Activation; Macrophages; Male; Metalloproteases; Myocardial Infarction; Natriuretic Peptide, Brain; Osteopontin; PPAR gamma; Rats; Rats, Sprague-Dawley; Survival Analysis; Telmisartan; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta1; Ventricular Remodeling | 2011 |
The cost implications of the use of telmisartan or ramipril in patients at high risk for vascular events: the ONTARGET study.
Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Cost of Illness; Diabetes Complications; Health Services; Heart Failure; Humans; Multicenter Studies as Topic; Myocardial Infarction; Ramipril; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Telmisartan | 2011 |
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure; Brain Ischemia; Clopidogrel; Diastole; Dipyridamole; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Recurrence; Reference Values; Risk; Stroke; Systole; Telmisartan; Ticlopidine; Vascular Diseases | 2011 |
Different roles of PPAR-γ activity on physiological and pathological alteration after myocardial ischemia.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Anilides; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Calcium Channel Blockers; Cells, Cultured; Disease Models, Animal; Drug Partial Agonism; Fibrosis; Hypertrophy, Left Ventricular; Male; Matrix Metalloproteinase 2; Myocardial Infarction; Myocardium; Pioglitazone; PPAR gamma; Rats; Rats, Sprague-Dawley; Stroke Volume; Telmisartan; Thiazolidinediones; Time Factors; Ventricular Function, Left; Ventricular Remodeling | 2012 |
The angiotensin receptor blocker and PPAR-γ agonist, telmisartan, delays inactivation of voltage-gated sodium channel in rat heart: novel mechanism of drug action.
Topics: Action Potentials; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Calcium; Cell Death; Heart; Losartan; Male; Myocardial Infarction; Myocytes, Cardiac; PPAR gamma; Rats; Rats, Sprague-Dawley; Sarcolemma; Sodium; Sodium-Calcium Exchanger; Telmisartan; Voltage-Gated Sodium Channels | 2012 |
[These hypertensive patients are especially at risk for myocardial infarct in the morning. Screen for non-dippers].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Circadian Rhythm; Clinical Trials as Topic; Humans; Hypertension; Myocardial Infarction; Risk Factors; Telmisartan | 2002 |
[Therapy of hypertension. Lasting organ protection moves into the foreground].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Clinical Trials as Topic; Drug Therapy, Combination; Heart Failure; Humans; Hypertension; Myocardial Infarction; Ramipril; Receptor, Angiotensin, Type 1; Stroke; Telmisartan; Treatment Outcome | 2003 |
[Vascular patient with high infarction risk. Does the AT-1 blocker protect as well as an ACE inhibitor?].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Cardiovascular Diseases; Diabetes Complications; Drug Therapy, Combination; Humans; Myocardial Infarction; Placebos; Ramipril; Randomized Controlled Trials as Topic; Risk Factors; Telmisartan; Time Factors | 2003 |
Regulation of proangiogenic factor CCN1 in cardiac muscle: impact of ischemia, pressure overload, and neurohumoral activation.
Topics: Alkaloids; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Benzophenanthridines; Cell Movement; Cells, Cultured; Cysteine-Rich Protein 61; Flavonoids; Gene Expression Regulation; Humans; Immediate-Early Proteins; Intercellular Signaling Peptides and Proteins; Interleukin-6; Leukemia Inhibitory Factor; Male; Mice; Mice, Inbred C57BL; Myocardial Infarction; Myocardial Ischemia; Myocardium; Myocytes, Cardiac; Myocytes, Smooth Muscle; Naphthalenes; Neovascularization, Physiologic; Norepinephrine; Paracrine Communication; Phenanthridines; Phenylephrine; Protein Kinase C; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptors, G-Protein-Coupled; RNA, Messenger; Stress, Mechanical; Telmisartan; Tumor Necrosis Factor-alpha | 2004 |
Impact of telmisartan on coronary stenting in patients with acute myocardial infarction compared with enalapril.
Topics: Angioplasty, Balloon, Coronary; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Coronary Restenosis; Enalapril; Female; Humans; Incidence; Japan; Male; Middle Aged; Myocardial Infarction; Retrospective Studies; Stents; Telmisartan | 2009 |
[Angiotensin II antagonism. Critical morning hours are covered].
Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Circadian Rhythm; Humans; Hypertension; Myocardial Infarction; Stroke; Telmisartan | 2001 |